EP
CRDF icon

Essential Partners’s Cardiff Oncology CRDF Stock Holding History

Essential Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$679 Sell
561
-1,524
-73% -$1.63K ﹤0.01% 2302
2026
Q2 		$2.71K Sell
2,085
-482
-19% -$765 ﹤0.01% 1846
2026
Q1 		$4.16K Buy
+2,567
New +$5.27K ﹤0.01% 1665

Other funds holding CRDF

GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return
Baker Ellis Asset Management
Baker Ellis Asset Management Vancouver, Washington $917M AUM 26.82% 1-Year Est. Return
Capital Advisors Wealth Management
Capital Advisors Wealth Management Yakima, Washington $888M AUM 16.06% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's CRDF Position: Q3 2026 in Review

Essential Partners reduced its Cardiff Oncology (CRDF) stake by 73% in Q3 2026, selling an estimated $1.63K and leaving 561 shares worth $679. The position accounts for ﹤0.01% of the portfolio, ranked #2302.

Essential Partners first reported a position in CRDF in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.16K in Q1 2026. 11 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

  • Essential Partners held 561 shares of Cardiff Oncology worth $679 as of Q3 2026.
  • Essential Partners sold 1,524 Cardiff Oncology shares in Q3 2026, an estimated $1.63K.
  • Cardiff Oncology made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2302 holding.
  • Essential Partners first reported a position in Cardiff Oncology in Q1 2026 and has held it in 3 quarters since.
  • Essential Partners's Cardiff Oncology position peaked at $4.16K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.